Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
Laevoroc – a company focused on oncology development – has announced the publication of key preclinical data carried out at the University of California (UCLA).